Sociedad Americana de Hirudoterapia

Determination of disulfide linkages in antimicrobial peptides of the macin family by combination of top-down and bottom-up proteomics

Proteomics article published in Journal of Proteomics (2014)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenómica y proteómicaFarmacología salivalResistencia antimicrobianaHung CW, Jung S, Grötzinger J, Gelhaus C, Leippe M, Tholey A · Journal of proteomics, 2014

Abstract

UNLABELLED: Macins are a distinct class of antimicrobial peptides (AMPs) produced by leeches and Hydra. Their function depends strongly on their three-dimensional structure. In order to support structural elucidation of these AMPs, the knowledge and proper assignment of disulfide bonds formed in these cysteine-rich peptides is a prerequisite. In this report, we outline an analytical strategy, encompassing a combination of top-down MS based analytics and sequence-dependent enzyme cleavage under native conditions followed by high mass accuracy and high resolution MS/MS analysis by LTQ-Orbitrap MS to assign disulfide linkages of three members of the macin family, namely neuromacin, theromacin, and hydramacin-1. The results revealed that the eight cysteine residues conserved in all three macins form the same four disulfide bonds, i.e. [C1:C6], [C2:C5], [C3:C7], and [C4:C8]. Theromacin, which possess two additional cysteine residues, forms a fifth disulfide bond. BIOLOGICAL SIGNIFICANCE: Beside the high biological significance which is based on the inherent dependence of biological activity on the structural features of antimicrobial peptides (which holds true for entirely every protein), the presented analytical strategy will be of wide interest, as it widens the available toolbox for the analysis of this important posttranslational modification.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAmino Acid SequenceAntimicrobial Cationic PeptidesDisulfidesMolecular WeightProteomicsSequence AlignmentTandem Mass Spectrometry

Resumen

Combined top-down and bottom-up mass spectrometry resolves the disulfide-bond architecture of leech-derived macin family antimicrobial peptides neuromacin, theromacin, and hydramacin-1, anchoring their structure-function relationships.

Por qué esto importa para la hirudoterapia

This study applied top-down mass spectrometry-based analytics combined with sequence-dependent enzyme cleavage under native conditions, followed by high mass accuracy and high resolution MS/MS analysis, to determine the disulfide bond arrangements in three members of the macin family of antimicrobial peptides: neuromacin, theromacin, and hydramacin-1. All three peptides share eight conserved cysteine residues forming identical disulfide bonds ([C1:C6], [C2:C5], [C3:C7], [C4:C8]), while theromacin possesses two additional cysteines forming a fifth disulfide bond. Macins are antimicrobial peptides produced by leeches and Hydra. This structural characterization is relevant to understanding the properties of antimicrobial peptides derived from leeches, though this is an analytical chemistry study with no functional antimicrobial activity data, therapeutic applications, or clinical relevance presented, and the connection to hirudotherapy is indirect.

Citación

Determination of disulfide linkages in antimicrobial peptides of the macin family by combination of top-down and bottom-up proteomics.

Hung CW, Jung S, Grötzinger J, Gelhaus C, Leippe M, Tholey A · Journal of proteomics, 2014

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 26, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.